Andrew J. Norris'  Instablog

Andrew J. Norris
Send Message
I research early (micro cap) and mid phase publicly traded companies in the Biotechnology and Medical Device sectors that are harder to at times find information on for investors. I believe that these companies, although potentially more volatile than their larger cap retail counterparts, hold... More
My blog:
Andrews Blog
  • The Hidden Cost Of Drug Development! 0 comments
    Mar 20, 2012 1:44 PM | about stocks: AZN, AMGN

    A Forbes article noted that over the past 15 years, the number of new drugs approved per big pharma company vs. the R&D expenditure for the same resulted in a very big number in dollars...upwards of close to $12B spent per drug. The data was highly variable spanning the worst at $11.7B R&D dollars per NME (new medical entity) [AstraZeneca] (NYSE:AZN), to Amgen's (NASDAQ:AMGN) $3.7B in R&D spent per NME approved. I was originally alerted to this information by Linda Pullan

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Stocks: AZN, AMGN
Back To Andrew J. Norris' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.